AMPA receptor agonists, antagonists and modulators: their potential for clinical utility
- 1 October 1997
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 7 (10) , 1099-1114
- https://doi.org/10.1517/13543776.7.10.1099
Abstract
Ligands with four pharmacologically distinct actions at the AMPA receptor are discussed. The four classes of compounds include agonists, antagonists, positive allosteric modulators, and negative allosteric modulators of AMPA receptor function. To date, no partial agonists have been discovered. Agonists and positive allosteric modulators may have therapeutic potential in disease states where hypoactivity of glutamatergic tone exists. From our understanding of neuronal circuitry and its involvement in brain function, agonists and positive allosteric modulators are predicted to improve the negative symptomatology in schizophrenia, and to improve memory, behavioural and cognition skills in dementias associated with neurodegenerative disorders or trauma. Issues related to the structural overlap of competitive AMPA receptor antagonists and NMDA glycine site (GlyN) antagonists are addressed; emphasis is directed toward AMPA antagonist activity. Competitive antagonists and negative allosteric modulators (non-competitive antagonists) have consistently demonstrated efficacy as neuroprotective agents in models of stroke, heart attack, and brain injury. Agents from the two classes of antagonist have been selected for clinical development, and some have entered clinical trials. At least one positive allosteric modulator is in clinical trials to determine whether it can improve clinical end-points in patients with Alzheimer’s disease. No agonist has been investigated in clinical trials.Keywords
This publication has 20 references indexed in Scilit:
- Conformational analysis of glutamic acid analogues as probes of glutamate receptors using molecular modelling and NMR methods. Comparison with specific agonistsBioorganic & Medicinal Chemistry, 1997
- AMPA Receptor Agonists: Synthesis, Protolytic Properties, and Pharmacology of 3-Isothiazolol Bioisosteres of Glutamic AcidJournal of Medicinal Chemistry, 1997
- Pyrrolylquinoxalinediones: A new class of AMPA receptor antagonistsBioorganic & Medicinal Chemistry Letters, 1996
- Syntheses of trans-3′-substituted-CCG-IV analogs and their characterization to ionotropic glutamate receptorsBioorganic & Medicinal Chemistry Letters, 1996
- Synthesis and Pharmacology of Highly Selective Carboxy and Phosphono Isoxazole Amino Acid AMPA Receptor AntagonistsJournal of Medicinal Chemistry, 1996
- A 3-Amino-4-hydroxy-3-cyclobutene-1,2-dione-Containing Glutamate Analog Exhibiting High Affinity to Excitatory Amino Acid ReceptorsJournal of Medicinal Chemistry, 1995
- Structure-activity relationships of tricyclic quinoxalinediones as potent antagonists for the glycine binding site of the NMDA receptor 1Bioorganic & Medicinal Chemistry Letters, 1995
- Excitatory amino acid receptor ligands: Asymmetric synthesis, absolute stereochemistry and pharmacology of (R)- and (S)-homoibotenic acidBioorganic & Medicinal Chemistry, 1995
- Tricyclic Quinoxalinediones: 5,6-Dihydro-1H-pyrrolo[1,2,3-de]quinoxaline-2,3-diones and 6,7-Dihydro-1H,5H-pyrido[1,2,3-de]quinoxaline-2,3-diones as Potent Antagonists for the Glycine Binding Site of the NMDA ReceptorJournal of Medicinal Chemistry, 1994
- Quisqualic acid analogs: synthesis of .beta.-heterocyclic 2-aminopropanoic acid derivatives and their activity at a novel quisqualate-sensitized siteJournal of Medicinal Chemistry, 1992